Slightly Raising Our Novo Nordisk FVE to DKK 276 Following 1Q; Shares Look Slightly Overvalued
We're slightly raising our fair value estimate for Novo Nordisk to DKK 276 from DKK 266 following a strong first quarter (no change to our $44.50 per ADR fair value estimate, due to exchange rate fluctuations). Management narrowed its 2018 guidance range for sales growth (from 2%-5% to 3%-5%) and operating profit growth (from 1%-5% to 2%-5%) as the firm locked in another relatively solid quarter for its hemophilia franchise ahead of heavier expected competition from Roche's Hemlibra, as well as ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.